ROS1 fusion gene in targeted therapy of nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2017.10.015

Abstract

Abstract: The molecular target therapy of nonsmall cell lung cancer (NSCLC) has become a hot research direction in the field of medicine. Following the discovery of wellknown tumordriven genes such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS) and anaplastic lymphoma kinase (ALK) genes, more and more scholars have shifted focus to ROS1 fusion gene. The protein encoded by ROS1 is a member of the receptor tyrosine kinase super family, and it plays an important role in cell growth and cell survival. ROS1 fusion gene plays a vital role in the occurrence, development and clinical treatment of NSCLC.

Key words: Carcinoma, nonsmallcell lung, ROS1 fusion gene, Crizotinib, Molecular targeted therapy

Chuang Xin, Jin Bo. ROS1 fusion gene in targeted therapy of nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(10): 783-786.

References

［1］蔡微菁, 粟波. 非小细胞肺癌的全新靶点ROS1融合基因［J］. 中华肿瘤杂志, 2013, 35(1): 14. DOI: 10.3760/cma.j.issn.02533766.2013.01.001. ［2］ Rikova K, Guo AL, Zeng QF, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer［J］. Cell, 2007, 131(6): 11901203. DOI: 10.1016/j.cell.2007.11.025. ［3］ Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1positive tumors in nonsmall cell lung cancer: identification of a FIGROS1 fusion［J］. Clin Cancer Res, 2012, 18(16): 44494457. DOI: 10.1158/10780432.CCR113351. ［4］ Govindan R, Ding L, Griffith M, et al. Genomic landscape of nonsmall cell lung cancer in smokers and neversmokers［J］. Cell, 2012, 150(6): 11211134. DOI: 10.1016/j.cell.2012.08.024. ［5］ MescamMancini L, Lantuéjoul S, MoroSibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1rearranged lung adenocarcinomas［J］. Lung Cancer, 2014, 83(2): 168173. DOI: 10.1016/j.lungcan.2013.11.019. ［6］ Yasuda H, De FigueiredoPontes LL, Kobayashi S, et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1translocated lung cancer［J］. J Thorac Oncol, 2012, 7(7): 10861090. DOI: 10.1097/JTO.0b013e3182570919. ［7］ Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers［J］. J Clin Oncol, 2012, 30(8): 863870. DOI: 10.1200/JCO.2011.35.6345. ［8］朱海波, 徐小玉, 王玲. 克里唑替尼治疗晚期非小细胞肺癌的临床研究进展［J］. 中国肺癌杂志, 2013, 16(6): 321324. DOI: 10.3779/j.issn.10093419.2013.06.09. ［9］宋勇, 杨雯. 2014年晚期非小细胞肺癌内科治疗进展［J］. 解放军医学杂志, 2015, 40(1): 1015. DOI: 10.11855/j.issn.05777402.2015.01.03. ［10］ Goodwin S, Mcpherson JD, Mccombie WR. Coming of age: ten years of nextgeneration sequencing technologies［J］. Nat Rev Genet, 2016, 17(6): 333351. DOI: 10.1038/nrg.2016.49. ［11］ Bos M, Gardizi M, Schildhaus HU, et al. Complete metabolic response in a patient with repeatedly relapsed nonsmall cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib［J］. Lung Cancer, 2013, 81(1): 142143. DOI: 10.1016/j.lungcan.2013.02.018. ［12］ Chiari R, Buttitta F, Iacono D, et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization and immunohistochemistrypositive lung adenocarcinoma: a case series［J］. Clin Lung Cancer, 2014, 15(6): 470474. DOI: 10.1016/j.cllc.2014.06.004. ［13］ Kazandjian D, Blumenthal GM, Luo L, et al. Benefitrisk summary of crizotinib for the treatment of patients with ROS1 alterationpositive, metastatic nonsmall cell lung cancer［J］. Oncologist, 2016, 21(8): 974980. DOI: 10.1634/theoncologist.20160101. ［14］ Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in nonsmall cell lung cancer［J］. Cancer Discov, 2013, 3(4): 430443. DOI: 10.1158/21598290.CD120440. ［15］ Ajimizu H, Kim YH, Mishima M. Rapid response of brain metastases to alectinib in a patient with nonsmallcell lung cancer resistant to crizotinib［J］. Med Oncol, 2015, 32(2): 477. DOI: 10.1007/s1203201404777. ［16］ Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins［J］. Proc Natl Acad Sci USA, 2013, 110(48): 1951919524. DOI: 10.1073/pnas.1319583110. ［17］ Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1rearranged nonsmallcell lung cancer［J］. N Engl J Med, 2014, 371(21): 19631971. DOI: 10.1056/NEJMoa1406766. ［18］ Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: nonsmall cell lung cancer, version 4.2016［J］. J Natl Compr Canc Netw, 2016, 14(3): 255264. ［19］ Awad MM, Katayama R, Mctigue M, et al. Acquired resistance to crizotinib from a mutation in CD74ROS1［J］. N Engl J Med, 2013, 368(25): 23952401. DOI: 10.1056/NEJMoa1215530. ［20］ Sun H, Li Y, Tian S, et al. Ploop conformation governed crizotinib resistance in G2032Rmutated ROS1 tyrosine kinase: clues from free energy landscape［J］. PLoS Comput Biol, 2014, 10(7): e1003729. DOI: 10.1371/journal.pcbi.1003729. ［21］ Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in nonsmall cell lung cancer［J］. PLoS One, 2013, 8(12): e82236. DOI: 10.1371/journal.pone.0082236. ［22］ Yu H, Li Y, Ge Y, et al. Novel 4anilinoquinazoline derivatives featuring an 1adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines［J］. Eur J Med Chem, 2016, 110: 195203. DOI: 10.1016/j.ejmech.2016.01.045. ［23］ Takegawa N, Hayashi H, Iizuka N, et al. Transformation of ALK rearrangementpositive adenocarcinoma to smallcell lung cancer in association with acquired resistance to alectinib［J］. Ann Oncol, 2016, 27(5): 953955. DOI: 10.1093/annonc/mdw032.

[1]	Jin Yao, Weng Yiming, Xu Zexi, Peng Min. Research progress on targeted treatment in ROS1-positive non-small cell lung cancer [J]. Journal of International Oncology, 2019, 46(12): 745-749.
[2]	LIANG Hong-Ge, XU Yan-Zhong, WEI Zhao-Jing, CHEN Min-Jiang, WANG Hua-Zhu, WANG Meng-Zhao. Evaluation of efficacy and safety of crizotinib and its prognostic factors in patients with ALKpositive advanced nonsmall cell lung cancer [J]. Journal of International Oncology, 2017, 44(5): 336-341.